Florida SB 1070: State Group Insurance Program Coverage for Obesity Treatment

Bill Text

1070 
State Group Insurance Program Coverage for Obesity Treatment 
2026-01-05T07:52:06Z 
Requiring the Department of Management Services to provide coverage for specified strategies for the evidence-based treatment and management of obesity and related conditions for state group health insurance plan policies issued on or after a specified date; prohibiting coverage criteria for weight management medications from being more restrictive than the United States Food and Drug Administration’s indications for such medications, etc. 
Original Filed Version 
2026 
S 
2026-07-01T00:00:00Z 
GB 
General Bill 
__ 

 Florida Senate - 2026 SB 1070 

 By Senator Rodriguez 

 40-00575B-26 20261070__ 
 1 A bill to be entitled 
 2 An act relating to state group insurance program 
 3 coverage for obesity treatment; amending s. 110.12303, 
 4 F.S.; requiring the Department of Management Services 
 5 to provide coverage for specified strategies for the 
 6 evidence-based treatment and management of obesity and 
 7 related conditions for state group health insurance 
 8 plan policies issued on or after a specified date; 
 9 prohibiting coverage criteria for weight management 
 10 medications from being more restrictive than the 
 11 United States Food and Drug Administration’s 
 12 indications for such medications; requiring the 
 13 department to adopt certain protocols and criteria by 
 14 a specified date; specifying such protocols and 
 15 criteria; defining terms; requiring the department to 
 16 submit a specified report to the Governor and 
 17 Legislature annually by a specified date; providing an 
 18 effective date. 
 19 
 20 Be It Enacted by the Legislature of the State of Florida: 
 21 
 22 Section 1. Subsection (9) is added to section 110.12303, 
 23 Florida Statutes, to read: 
 24 110.12303 State group insurance program; additional 
 25 benefits; price transparency program; reporting.— 
 26 (9)(a) For state group health insurance plan policies 
 27 issued on or after January 1, 2027, the department shall provide 
 28 coverage for all of the following evidence-based strategies for 
 29 the treatment and management of obesity and related conditions, 
 30 as prescribed by a licensed provider: 
 31 1. Intensive health behavioral and lifestyle intervention. 
 32 2. FDA-approved weight management medications. 
 33 (b) Coverage criteria for FDA-approved weight management 
 34 medications may not be more restrictive than the United States 
 35 Food and Drug Administration-approved indications for such 
 36 medications. Coverage for intensive health behavioral and 
 37 lifestyle treatment may include interventions certified or 
 38 recognized by the United States Centers for Disease Control and 
 39 Prevention or recommended by current clinical standards of care. 
 40 Services may be provided in an office setting, through 
 41 telehealth, or in community-based settings to support patient 
 42 access and needs. 
 43 (c) The department shall adopt protocols and criteria for 
 44 such coverage by January 1, 2027, which must include, but are 
 45 not limited to, that the employee: 
 46 1. Is enrolled in one of the state group health insurance 
 47 plans or HMO plans participating under this section; 
 48 2. Is 18 years of age or older; 
 49 3. Was referred and is supervised by an in-network licensed 
 50 provider; 
 51 4. Has consented to provide personal and medical 
 52 information to the department, including medical records 
 53 documenting body mass index or weight-related comorbidities; 
 54 5. Has received a clinical diagnosis of obesity by an in 
 55 network licensed provider; 
 56 6. Is required to participate in intensive health 
 57 behavioral and lifestyle intervention; and 
 58 7. Meets any additional clinical and participation 
 59 requirements to manage the cost of coverage. 
 60 (d) As used in this subsection, the term: 
 61 1. “FDA-approved weight management medication” means any 
 62 glucagon-like peptide-1 (GLP-1) agonist medication approved by 
 63 the United States Food and Drug Administration with an 
 64 indication for chronic weight management in patients with an 
 65 obesity diagnosis. 
 66 2. “Intensive health behavioral and lifestyle intervention” 
 67 means an evidence-based, intensive, multicomponent behavioral or 
 68 lifestyle modification intervention designed to support healthy 
 69 weight management as recommended by current clinical standards 
 70 of care. Interventions include obesity screening, nutrition 
 71 assessment, nutrition diagnosis, nutrition intervention, 
 72 nutrition monitoring and evaluation, and behavioral counseling 
 73 and therapy aimed at weight loss through lifestyle 
 74 modifications, such as changes in diet and increased physical 
 75 activity. Interventions may be provided in office, through 
 76 telehealth, or in community-based settings to support patient 
 77 access and needs. Therapy for obesity must be delivered in 
 78 accordance with applicable national clini